Spinning out

Our staff and students frequently go on to forge their own ventures, starting something of their own that has the potential to transform the lives of countless others.

In recent years, harnessing that enterprising spirit has become increasingly important at the University of Dundee, which supports the spinouts and start-ups of its staff and students via its Research & Innovation Services (RIS) and Centre for Entrepreneurship (CfE). The University’s commitment is evidenced in the success of several spinout and start-up companies that are already making huge waves in the world of business.

It’s a commitment that is already paying dividends, with the University last year being named as one of the UK’s most successful at commercialising its research, raising more than £325 million over the past two decades.

We were ranked among the very best universities in the UK at commercialising research in the University Spinout Report 2021 delivered by GovGrant. We were also named fifth overall in the UK for our record in turning research into world-changing companies, ahead of universities such as Oxford, King’s College London, and Imperial College London, in the ‘Spinning out Success’ report, produced by Octopus Ventures.

"Dundee has a long-standing track record of commercial success and tangible impact from genuinely world-class research, particularly from its Schools of Life Sciences and Medicine," said Dr David McBeth, Director of Research & Innovation Services at the University.

"At present, we have several high-growth spinouts making real strides commercially, our pipeline has never been stronger, and we are always on the lookout for entrepreneurial management talent."

Companies such as Exscientia and Amphista Therapeutics have recently ‘spun out’ from our world-leading research facilities to great success in the application of Artificial Intelligence and new generation therapeutics to drug discovery.

Last year saw the drug discovery firm Exscientia achieve an Initial Public Offering (IPO) on the US NASDAQ stock exchange that valued the company at over £2.2 billion. This staggering success saw Exscientia claim a hugely prestigious award, Global University Venturing’s Deal of the Year for 2021.

Spun out from the University in 2012, Exscientia was founded by the School of Life Sciences’ Professor Andrew Hopkins. It was the first company to use Artificial Intelligence to automate drug design from idea to the pre-clinical candidate stage and its advanced AI has the ability to significantly speed up drug development, an expensive undertaking for pharmaceutical companies.

Exscientia is now one of the biggest life sciences spin-out companies to emerge from UK higher education, a true 'unicorn' company.

Amphista Therapeutics, a spin-out from the laboratory of Professor Alessio Ciulli in the School of Life Sciences, is another which is gathering significant momentum. In May they announced they will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion. As part of separate partnerships, Amphista will collaborate with Merck Healthcare and Bristol Myers Squibb to leverage the company’s targeted protein degradation (TPD) technology and generate therapeutics in multiple disease areas.

Amphista creates first-in-class therapeutics that harness the body’s natural processes to degrade and remove disease-causing proteins selectively and efficiently.

There will be more on the way as we continue to look to maximise the impact of our research. Dr McBeth said, "World-leading research is taking place at the University every day, and commercialisation of this allows us to build companies that have the ability to change lives around the world. We are able to help spinouts by connecting them with funding networks and industry expertise, giving them the best chance of turning promising ideas into successful businesses."